The molecular correlate of the calcium release-activated calcium current (I CRAC ), the channel protein Orai1, is upregulated in proliferative vascular smooth muscle cells (VSMC). However, the role of Orai1 in vascular disease remains largely unknown.
V ascular smooth muscle cell (VSMC) proliferation is a major contributor to vascular occlusive diseases such as atherosclerosis, hypertension, and neointimal hyperplasia after angioplasty. Damage to blood vessel walls triggers pathological changes that include the switch of medial VSMC from a contractile to a synthetic phenotype. In response to injury, VSMCs proliferate and migrate across the internal elastic lamina toward the vascular lumen, produce extracellular matrix, form the structure called neointima, and result in narrowing of vessel lumen with devastating consequences on cardiovascular function.
Calcium (Ca 2ϩ ) signaling plays an essential role in VSMC phenotypic changes. 1 A major Ca 2ϩ influx pathway activated in response to extracellular agonits is the store-operated Ca 2ϩ entry (SOCE) pathway, which is initiated by phospholipase C (PLC) activation and subsequent IP 3 -mediated discharge of internal Ca 2ϩ stores. [2] [3] [4] [5] SOCE is associated with a highly Ca 2ϩ selective conductance called Ca 2ϩ release-activated Ca 2ϩ current (I CRAC ), first identified in mast cells 6 and subsequently in other cell types, including VSMC. [7] [8] [9] The molecular components of I CRAC have been recently discovered and belong to 2 protein families: the Ca 2ϩ sensor STIM1 located mainly in the endoplasmic reticulum (ER) 10, 11 and the Ca 2ϩ channel Orai1 expressed at the plasma membrane (PM). [12] [13] [14] Decrease of Ca 2ϩ concentration within the lumen of the ER causes STIM1 to reorganize into punctate structures and relocate to discrete regions of close ER/PM contacts to activate Orai1 through binding of a minimal 107 amino acids C-terminal region of STIM1 (called SOAR/CAD) 15, 16 to the C-and N-termini of Orai1. Mammals have another STIM protein, STIM2, and 2 Orai proteins, Orai2 and Orai3, that are also activated by STIM proteins when ectopically coexpressed in the HEK293 system. We have recently provided evidence for an endogenous I CRAC -like current encoded by Orai3 17 while Orai2 contribution to native Ca 2ϩ conductances remains unknown. Members of the transient receptor potential canonical (TRPC) family of cation channels have also been suggested to be the molecular correlates of nonselective SOCE conductances that are distinct from I CRAC . 18, 19 We and others have demonstrated that Orai1 and STIM1 are upregulated in synthetic proliferative VSMCs. 9, 20 Data from our laboratory showed that either STIM1 or Orai1 knockdown using silencing RNA (siRNA) inhibited SOCE, I CRAC , and synthetic VSMC proliferation and migration in response to serum and platelet-derived growth factor (PDGF). 9 , 21 We also showed that Orai1 and STIM1 were upregulated in medial and neointimal VSMC from rat carotids after balloon injury, 21 suggesting that these proteins are involved in vascular pathophysiology. Interestingly, 2 recent reports have specifically addressed the role of STIM1 in VSMC remodeling in vivo and independently reported that STIM1 in vivo knockdown inhibited neointima formation after balloon injury in rat carotids. 22, 23 However, the mechanism of action of STIM1 and the exact PM ion channel that mediates STIM1 function during VSMC remodeling in vivo is unclear. In addition to its role in activating Orai1-mediated I CRAC , STIM1 positively regulates the function of Orai2, Orai3, and Orai1/ Orai3 heteromultimeric channels in their store-operated mode 24 -27 and that of the store-independent Orai1/Orai3 arachidonate-regulated Ca 2ϩ (ARC) channel 28 as well as that of most TRPC channels. 18, 29, 30 Furthermore, STIM1 has recently been shown to regulate the function of L-type Ca 2ϩ channels in different cell types, including VSMCs. 31, 32 The significance of Orai1 upregulation during vascular injury, its interdependence on STIM1, and its role in VSMC remodeling and neointima formation in vivo is an important question that has remained unanswered. Therefore, in this study we comparatively tested the role of Orai1 and STIM1 in VSMC proliferation and neointima formation in vivo using the rat carotid artery balloon-injury model. We found that either Orai1 or STIM1 in vivo knockdown is sufficient to inhibit VSMC proliferation and neointima formation to a similar extent. We show that Orai1 is required for nuclear translocation and activation of nuclear factor for activated T cells (NFAT) in VSMCs. Furthermore, we report that Orai1 and STIM1 upregulation is also a feature of another model of vascular remodeling: the carotid ligation in mice, highlighting the importance of Orai1-mediated I CRAC in smooth muscle phenotypic switching and unraveling Orai1 as a potential target for vascular occlusive diseases.
Methods
All antibodies/reagents concentrations, dilutions, and origins are described in detail in the Online Data Supplement available at http://circres.ahajournals.org. Cell culture, generation of lentiviruses, and surgeries were conducted using standard procedures. An expanded material and methods section is presented in the Online Supplement.
Results

VSMC Orai1 and STIM1 Knockdown Using Lentiviral Particles-Encoding shRNA Abrogates SOCE and I CRAC
ShRNA sequences targeting either Orai1 or STIM1 were cloned under the control of the H1 promoter in the lentiviral vector pFUGW-GFP, which separately encodes green fluorescent protein (GFP) under the control of the Ub-c promoter. Lentiviral particles were produced and used to infect synthetic cultured rat aortic VSMCs. These viral particles were efficient at infecting 90% to 95% of VSMCs, as visualized by GFP fluorescence ( Figure 1A ). Infection of VSMC with either shOrai1 or shSTIM1 viruses caused marked decrease in cell number ( Figure 1A) , consistent with previous studies demonstrating a role for Orai1/STIM1 in VSMC proliferation. 9, 21 Real-time PCR showed that shOrai1 viruses reduced their respective mRNA levels with no significant effect on STIM1 mRNA levels; similar results were obtained with shSTIM1 viruses (Figure 1B ). Orai1 and STIM1 protein knockdown after shRNA treatment was documented by Western blotting ( Figure 1C and 1D ). ShOrai1 viruses reduced Orai1 mRNA and protein levels by 88.7%Ϯ0.76% and 67.4%Ϯ9.34%, respectively, and shSTIM1 viruses reduced STIM1 mRNA and protein levels by 88.8%Ϯ0.53% and 98.1%Ϯ0.66%, respectively; nϭ3 ( Figure 1B and 1D) . Furthermore, shOrai1 had no significant effect on expression of Orai2 and Orai3 homologs as measured using real-time PCR (Supplemental Figure IA) , ruling out potential cross-effects of shOrai1 on Orai2 and Orai3. Ca 2ϩ imaging was performed on selected VSMCs displaying strong GFP fluorescence, thus selecting only cells with almost complete knockdown. ShOrai1 and shSTIM1 viruses inhibited the extent of SOCE activated by thapsigargin in VSMC by 87.7%Ϯ2.38% and 74.8%Ϯ2.98%, nϭ21 and 19, respectively, in comparison with cells infected with shLuciferase lentivirus ( Figure 1E and 1F); the remaining SOCE in cells infected with shSTIM1 viruses despite almost complete STIM1 protein downregulation is likely due to native STIM2, consistent with previous studies. 10 The inhibition of SOCE on Orai1 knockdown could be effectively rescued by expressing siRNA-resistant cyan fluorescent protein (CFP)-Orai1clone in VSMC (Supplemental Figure IB and IC). Previous studies from our laboratory and others have shown that Orai2 and Orai3 do not contribute to SOCE in rat and human VSMCs. 9, 21, 33 Importantly, shOrai1 and shSTIM1 viruses dramatically inhibited I CRAC (by comparison with shLuciferase) measured by whole cell patch clamp after passive store depletion with dialysis of 20 mmol/L of the chelator BAPTA through the patch pipette ( Figure 1G through 1K 
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solution containing 20 mmol/L Ca 2ϩ (Ca 2ϩ I CRAC ) and was amplified using short pulses (30 seconds) of standard divalent-free (DVF; Na ϩ I CRAC ) solutions as described previously. 8, 9 I CRAC showed typical current depotentiation in DVF solutions ( Figure 1G Figure 1J ; statistical analyses on Na ϩ I CRAC recordings from different cells are shown in Figure 1K .
Rat Carotid Balloon Injury Causes Increased Orai1/STIM1 Protein Expression and VSMC Proliferation
We performed balloon injury on rat left carotids as described in Methods; right carotids were used as internal controls. Carotid injury causes significant neointima formation at 7 and Na ϩ I CRAC currents recorded in divalent free (DVF) external solutions, from shOrai1Ϫ (nϭ4) and shSTIM1-infected VSMCs (nϭ5) in comparison with shLuciferase-infected VSMCs (nϭ3). A DVF pulse was applied immediately after break-in to gauge leak current, which was subsequently subtracted from the DVF current obtained after store depletion. J, I/V relationships of Na ϩ I CRAC from VSMCs infected with shLuciferase, shOrai1, or shSTIM1 lentiviruses were taken where indicated by the color-coded asterisks. K, Statistical analyses on Ca 2ϩ I CRAC and Na ϩ I CRAC currents taken at Ϫ100 mV from several independent VSMCs infected with shLuciferase, shOrai1, or shSTIM1 lentiviruses.
days postinjury with peak neointima observed at 14 days postinjury (Figure 2A) , consistent with previous studies. 34 Left injured and right control carotid arteries were isolated, sectioned, and subjected to immunofluorescence (IF) staining using Orai1, STIM1, Ki67, and myosin heavy chain (MHC) specific antibodies, as described in the Methods. Figure 2B shows IF staining on carotid arteries 7 days postinjury in which Orai1 and STIM1 proteins are clearly upregulated in neointimal VSMCs from left injured carotid arteries in comparison with right control carotids. Orai1/STIM1 protein upregulation in neointimal VSMCs from injured left carotids in comparison with medial VSMCs from right carotids was confirmed by Western blotting 14 days postinjury ( Figure  2C ). Western blots also show increased expression of proliferating cell nuclear antigen (PCNA) in injured carotids at day 14 postinjury, suggesting increased cell proliferation ( Figure   2C ). Ki67 staining was used as an additional marker of cell proliferation at 7 days postinjury and clearly shows positive staining of neointimal VSMCs from injured left carotids while right carotids display no significant Ki67 expression. Although right control carotids show robust staining of the contractile VSMC marker MHC in the media layer, injured left carotids show reduced MHC staining in medial VSMCs and dramatic decrease in the neointimal layer ( Figure 2B ).
Effects of in Vivo Infection With shOrai1 and shSTIM1 Lentiviruses on VSMC Proliferation and Protein Expression
A series of vascular injury experiments were conducted on left carotids of rats to evaluate the effect of in vivo knockdown of Orai1 and STIM1 on VSMC proliferation and protein expression. Left carotids were injured and treated 
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with either shLuciferase, shOrai1, or shSTIM1 lentiviruses for 30 minutes as outlined in the Methods; right carotids were neither injured nor treated with lentiviruses (NT) and were used throughout as internal controls. As shown in Figure 3A , left carotid arteries were successfully infected by lentiviruses as demonstrated by positive expression of GFP; right noninjured and noninfected show no GFP expression ( Figure 3A ). Immunohistochemistry (IHC) showed positive GFP staining in vessel sections injured and treated with shOrai1 lentiviruses (Supplemental Figure II) . Injured left carotid arteries treated with shLuciferase show a dramatic increase in protein expression of Orai1 and STIM1. These injured shLuciferasetreated carotids also showed upregulation of the CamKII␦2 isoform, a major downstream effector of Ca 2ϩ signaling in synthetic VSMCs and an important determinant in neointima formation. 34, 35 Importantly, injured shLuciferase-treated left carotids showed increased PCNA expression, indicating increased VSMC proliferation after injury. Treatment of injured left carotids with shOrai1 lentiviral particles substantially prevented the upregulation of Orai1 protein and the proliferative marker PCNA 14 day postinjury ( Figure 3A and 3B). Interestingly, shOrai1 also prevented upregulation of STIM1 and CamKII␦2 proteins. This is in contrast to in vitro knockdown of Orai1 in proliferative VSMCs, which had no effect on STIM1 or Orai2/3 expression ( Figure 1B and Supplemental Figure IA) , suggesting that chronic in vivo Orai1 knockdown is complex and prevents VSMC from injured carotids to acquire markers associated with switch to proliferative phenotypes ( Figure 3A and 3B). In a manner similar to shOrai1, shSTIM1 was able to substantially prevent STIM1, Orai1, PCNA, and CamKII␦2 upregulation ( Figure 3A and 3B) . Figure 3B shows statistical analysis on Western blotting densitometry of Orai1, STIM1, CamKII␦2, and PCNA proteins normalized to corresponding ␤-actin from 6 rats per condition. , and shSTIM1 lentiviruses efficiently infected carotid vessels as evidenced with expression of green fluorescent protein (GFP) in medial and neointimal protein extracts from left carotid arteries that are balloon injured (14 days after injury) and infected with viral particles; right noninfected carotids show no GFP expression. ShOrai1 inhibited upregulation of Orai1 protein as well as that of STIM1 and CamKII␦2, 14 days postinjury. Similarly, shSTIM1 inhibited upregulation of STIM1 protein as well as that of Orai1 and CamKII␦2. ShOrai1 and shSTIM1 inhibited VSMC proliferation as evidenced by reduced protein expression of proliferating cell nuclear antigen (PCNA) in medial and neointimal protein extracts from balloon-injured left carotids treated with shOrai1 and shSTIM1 lentiviruses in comparison withinjured left carotids treated with shLuciferase lentiviruses. B, Statistical analyses on Orai1, STIM1, CamKII␦2, and PCNA protein expression data on extracts of medial and neointimal VSMC from ballon-injured left carotids and treated with shLuciferase, shOrai1, or shSTIM1 lentiviruses. Data represent densitometry on protein bands with average ϮSEM from 6 rats per condition, determined using Image J and normalized to ␤actin expression. C through D, IF using specific anti-Orai1 (C) and anti-STIM1 (D) antibodies on left carotid sections (14 days after injury) injured and treated with shLuciferase, shOrai1, or shSTIM1 lentiviruses (bottom) and corresponding right noninjured nontreated control carotids (top).
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IF experiments using antibodies against Orai1, STIM1, and CamKII␦2 were performed on right (control) and left carotids (injured and treated with shRNA), 14 days postinjury ( Figure 3C and 3D). Orai1 ( Figure 3C 
Orai1 and STIM1 in Vivo Knockdown Prevents Neointima Formation
Left carotid injury followed by in vivo lentiviral infection with shLuciferase, shOrai1, and shSTIM1 were performed as described above. Figure 4A shows H&E staining of carotid artery cross-sections from sham-operated control noninjured (intact) and balloon-injured and treated with lentiviral particles encoding either shLuciferase (shLuc; nϭ7), shOrai1 (nϭ5) ,or shSTIM1 (nϭ5) 14 days after injury. Treatment with shOrai1 or shSTIM1 dramatically attenuated neointima formation in comparison with shLuciferase ( Figure 4A ). Figure 4B shows statistical analysis of neointima and media layer areas (in mm 2 ) from left injured carotids and intima and media layer areas from right noninjured carotids obtained from 5 to 7 independent rats per condition and determined using the Image J software. The size of neointima is dramatically increased 14 days after injury, and this increase is largely attenuated by shOrai1 and shSTIM1. However, the medial layer area from injured carotids treated with shLuciferase is not significantly different from that of carotids injured and treated with shOrai1 or shSTIM1 or that of noninjured right carotid controls ( Figure 4B ). Figure 4C represents statistical analysis of area ratios of neointima/ media (N/M) and clearly shows increased N/M ratios in injured and shLuciferase-treated left carotids; these N/M ratios were substantially reduced in left carotid arteries that were injured and treated with either shOrai1 or shSTIM1 lentiviruses ( Figure 4C ). Supplemental Table I depicts data on vessel and lumen size measurements from conditions.
We next sought to evaluate whether STIM1 and Orai1 contribution to VSMC proliferation is mediated by constitutive STIM1/Orai1-mediated SOCE due to precoupling of STIM1/Orai1 in synthetic proliferative VSMCs. We failed to detect any basal (in absence of store depletion) SOCE activity in synthetic VSMCs using either Ca 2ϩ imaging or patch clamp electrophysiology (Supplemental Figure V) . Confocal microscopy on ectopically expressed eYFP-STIM1 in VSMCs showed no STIM1 puncta under resting conditions; STIM1 puncta was observed only after thapsigargin treatment (Supplemental Figure VIA) . Similarly, coexpression of eYFP-STIM1 and CFP-Orai1 showed colocalization only after store depletion (Supplemental Figure VIB) , suggesting that the contribution of STIM1/Orai1 to VSMC remodeling is likely regulated by growth/vasoactive factors.
Orai1/STIM1 Knockdown Inhibits NFAT Nuclear Translocation and Activity
To delineate downstream pathways involved in Orai1-and I CRAC -mediated increase in VSMC proliferation, we sought to evaluate the contribution of VSMC Orai1-mediated I CRAC to the activation of the transcription factor, nuclear factor for activated T cells (NFAT), a known downstream target of I CRAC in lymphocytes. Synthetic VSMC were transfected with a plasmid encoding NFAT-GFP fusion protein and siOrai1, siSTIM1, or nontargeting control siRNA, and NFAT nuclear translocation was monitored by following GFP fluorescence before and after activation of SOCE by 2 mol/L thapsigargin for 15 minutes. Knockdown of either Orai1 (nϭ15) or STIM1 (nϭ11) drastically inhibited NFAT nuclear translocation in 
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comparison with siRNA control (nϭ28; Figure 5A and 5B). The average percentage of inhibition of NFAT nuclear translocation was 85.4% for siOrai1 and 92.3% for siSTIM1. We also used a luciferase reporter assay to directly measure NFAT activity on VSMC transfection with siOrai1, siSTIM1, or control siRNA as described in Methods. NFAT activity was determined using the NFAT-driven luciferase construct (pIL2-Luc) cotransfected with the Renilla-luciferase vector (as an internal control) in VSMC previously transfected with different siRNA. SiOrai1-(nϭ6) and siSTIM1-transfected VSMCs (nϭ4) displayed essentially abrogated luciferase activities in comparison with control siRNA-transfected cells (nϭ6; Figure 5C ).
Orai1/STIM1 Are Upregulated in Carotids From Mice Subjected to Ligation Injury
To determine a potential broader role of Orai1/STIM1, we investigated the upregulation of Orai1 and STIM1 in carotid artery sections from mice subjected to disturbed flow or increased shear stress due to carotid ligation. IHC staining with specific antibodies against Orai1 and STIM1 in ligationinjured carotids (at day 21 postligation) from mice shows marked upregulation of Orai1 and STIM1 proteins in media and neointima from ligation-injured carotids in comparison with control ( Figure 6 ); Orai1 and STIM1 staining was correlated with that of the VSMC marker smooth muscle ␣-actin (SM␣-actin) on contiguous sections, indicating that cells with upregulated Orai1 and STIM1 are VSMCs ( Figure 6 ). STIM1 staining in intact vessels was almost undetectable at the dilution of primary antibody used for injured sections (1:2000) and became visible at a dilution of primary antibody of 1:1200 (see Figure 6 , inset). These data suggest that Orai1 and STIM1 upregulation is a more general feature of VSMC remodeling shared by other models of vascular occlusive diseases.
Discussion
Orai1 and STIM1 have recently emerged as central molecular players for SOCE and I CRAC as well as store-independent ARC channels. 5, 36 Both Orai1 and STIM1 are upregulated in synthetic proliferative VSMC in comparison with quiescent freshly isolated VSMC. 9, 20 STIM1 is clearly regulating an increasing number of ion channels, and future research is likely to extend further the list of channels, transporters, and 24, 26 as well as the store-independent ARC channels mediated by Orai1/Orai3 heteromers. 28, 37 STIM1 also regulates the function of all TRPC channels, with the exception of TRPC7 18 and has recently been shown by 2 independent groups to control the function of L-type Ca 2ϩ channels. 31, 32 Therefore, this study set out to specifically test the involvement of Orai1 in neointima formation by comparison with STIM1 and to determine the significance of Orai1 upregulation in synthetic proliferative VSMC from injured arteries. Inhibition of Orai1 upregulation during carotid injury using lentiviral particles encoding shRNA prevented Orai1 protein increase 14 days postinjury. Interestingly, Orai1 in vivo knockdown also prevented upregulation of STIM1 and CamKII␦2. Importantly, Orai1 in vivo knockdown inhibited VSMC proliferation assessed by PCNA and dramatically reduced neointima formation. Both Orai1 and STIM1 knockdown inhibited NFAT nuclear translocation and transcriptional activity, providing a transcriptional pathway downstream of Orai1 and I CRAC -mediated Ca 2ϩ entry for the control of VSMC proliferation. The upregulation of Orai1 and STIM1 appears to be a feature of proliferative VSMC in other models of vascular diseases such as carotid ligation model in mice, highlighting the universality of I CRAC Ca 2ϩ entry pathway in VSMC remolding regardless of whether the trigger for this remodeling is acute mechanical injury with removal of endothelium or chronic disturbance of flow or shear stressinduced injury.
The fact that Orai1 knockdown is as efficient as STIM1 in preventing neointima formation in vivo suggests that Orai1 can be a potential target for treatment of VSMC remodeling during vascular diseases. Conceptually, Orai1 would offer a far better target than STIM1 for the following reasons: (1) by its virtue of being an ion channel expressed at the PM, Orai1 is more accessible than STIM1 that is mainly expressed in the ER and (2) targeting STIM1 could be associated with side effects because STIM1 is involved in controlling a plethora of ion channels in addition to Orai1-mediated I CRAC . However, Orai1 and I CRAC are prominently functional in the immune system; the main feature of Orai1-deficient patients and mice is severe immunodeficiency. 38 -40 Thus, although it is logical to presume that any potential drug against Orai1 and I CRAC in the treatment of VSMC remodeling is likely to be immunosuppressive, this might not be the case. Orai1 and I CRAC clearly mediate SOCE in both leukocytes (T cells, B cells, and mast cells) and VSMC, yet there is evidence suggesting that the molecular organization of Orai1 at the PM is distinct between VSMC and other cell types. Indeed, the nonspecific drug 2-aminoethoxydiphenyl borate (2-APB) completely abrogates SOCE in VSMC at low micromolar concentrations (2 to 5 mol/L), 9 but higher concentrations (30 to 50 mol/L) are required to inhibit SOCE in leukocytes and other cell types. 41 The reason for this difference is unknown but might be due to differences in posttranslational modifications of Orai1 or differential requirement of regulatory molecules between VSMC and other cell types. A recent report by Li et al showed that a SOCE inhibitor, S66, is more potent in endothelial cells than in immune cells, 42 despite the fact that Orai1 encodes SOCE and I CRAC in both cell types. 8, 12 This suggests that Orai1 and I CRAC in the vasculature might have subtle differences that would endow them with different sensitivities to drugs in comparison with other tissues.
In summary, this study provides evidence that Orai1 could be used as a target for vascular occlusive diseases. Future studies aimed at better understanding Orai1 molecular organization and its mechanisms of regulation in VSMC are likely to realize the use of Orai1 as an efficient target for treatment of vascular occlusive diseases.
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Novelty and Significance
What Is Known?
• Orai1 calcium (Ca 2ϩ ) channels are expressed in vascular smooth muscle cells (VSMC), and their expression is increased in proliferative migratory "synthetic" VSMC.
• Orai1 mediates calcium release-activated calcium (CRAC) current in VSMC that is required for VSMC proliferation and migration in vitro.
What New Information Does This Article Contribute?
• Balloon injury in rat carotids and carotid ligation in mice causes increased expression of Orai1 protein in medial and neointimal VSMC.
• Knockdown of Orai1 expression in vivo by transduction of lentivirusencoding shRNA into balloon-injured carotid arteries prevent Orai1, STIM1, and CamKII␦2 upregulation, VSMC proliferation in vivo, and neointima formation.
• Orai1 knockdown in VSMC inhibits the nuclear translocation and activity of the transcription factor, nuclear factor for activated T-cells (NFAT).
Orai1 and STIM1 are two critical components of the CRAC channel (I CRAC ) that regulate Ca 2ϩ entry in nonexcitable cells. The role of Orai1 in vascular function and disease is only beginning to emerge. Our work shows that Ca 2ϩ entry through Orai1 and I CRAC is essential for driving VSMC remodeling in vivo during vascular disease such as restenosis. In vivo knockdown of Orai1 by shRNA in a rat balloon injury model prevents upregulation of Orai1, STIM1, and CamKII␦2 in VSMC and inhibits VSMC proliferation and neointima formation. Orai1 knockdown in VSMC inhibits NFAT nuclear translocation and activation, providing a potential mechanism for Orai1-dependent regulation of VSMC remodeling. These findings reveal a role for Orai1 and I CRAC in driving VSMC proliferation during vascular disease. Orai1 targeting with specific drugs might have the potential for treatment of vascular occlusive diseases. Luciferase: CGTACGCGGAATACTTCGA Viral particles were generated using standard protocols. PolyJet was used as a transfection reagent (SignaGen) to transfect HEK293FT cells (Invitrogen). Briefly, the lentiviral constructs pCMV-VSVG, pCMV-dR8.2 and pFUGW-GFP-shSTIM1/shOrai1/shLuciferase were cotransfected into a flask of 95% confluent HEK293FT cells. Cell culture media with viral particles were collected at 48h and 72h after transfection and was concentrated using Amicon Ultra-15 filter by centrifugation.
Balloon Injury and Lentiviral Treatment
All Animals protocols, including surgeries were approved by the Institutional Animal Care and Use Committee at the Albany Medical College Animal Resource Facility, which is licensed by the USDA and N.Y.S. Department of Public Health, Division of Laboratories and Research. Male Sprague-Dawley rats (400~450g, Taconic Farms, Germantown, NY) were anesthetized with ketamine (80mg/kg) and xylazine (5mg/kg). Following a midline cervical incision and muscular tissues separation, the left common carotid artery was exposed and blunt dissection was performed alongside the artery by dull forceps to expose the carotid artery bifurcation into the internal/external branches. Blood flow cessation was performed by arterial clamps, with the following steps. A 2F Fogarty balloon catheter (Edwards) was introduced via a small arteriotomy in the external carotid artery and advanced to the common carotid artery. The balloon was inflated by 1.6atm pressure and was inserted and withdrawn three times. Sham-operated rats were treated in the same manner except that no balloon was inserted in the vessel. Concentrated lentiviral solutions encoding shOrai1, shSTIM1 or shLuciferase (50µl) were infused into the injured segment of the common carotid artery and incubated for 30 minutes. After the 30min viral treatment, leftover viral solutions in lumen were aspirated and disposed off to avoid dissemination of viral solutions into the systemic circulation. A permanent ligation was placed in the external carotid artery, and then blood flow in the common carotid artery and its internal branch was restored. Following the suturing of incision, rats were treated by the analgesic Buprenex (0.20mg/kg) delivered through intramuscular injection and allowed to recover.
Mice carotid artery ligation modelC57BL/6 male mice (3-4-month old) were anesthetized by intraperitoneal injection of a mixed solution of xylazine (5mg/kg body weight) and ketamine (80mg/kg body weight). The left common carotid artery was dissected and completely ligated near the carotid bifurcation.
Sections, Hematoxylin/Eosin staining, Immunofluorescence and Immunohisto-chemistry
Rats were euthanized at different time points by asphyxiation in a CO 2 chamber and fragments of carotid arteries were placed in a cryoprotective embedding medium OCT then snap frozen in liquid nitrogen. The specimen was then stored at -80⁰C or sectioned in a Leica CM3050 cryostat. Sections were treated by pre-cooled acetone for 10 minutes at 4⁰C and air dried. Mice with ligated carotids were sacrificed 21days after injury in CO 2 chamber and both the left (ligated) and right (intact, used as a control) carotid arteries were collected and embedded in paraffin. The specimen was then stored at -80⁰C or sectioned in a Leica CM3050 cryostat. Sections were treated by pre-cooled acetone for 10 minutes at 4⁰C and air dried. Hematoxylin/Eosin (H&E) staining was performed following standard protocols, except that the incubation time with Hematoxylin was increased to 3 minutes and the time with Eosin-Y was decreased to 15 seconds. For Immunofluorescence staining, the sections were fixed with the pre-cooled acetone for 10 minutes at 4 o C and rinsed with 1 x PBS. The sections were then incubated in a PBS washing buffer containing 0.1% Triton X-100 for 10 minutes. The sections were incubated for 30 minutes in blocking buffer (1 x PBS/5% goat serum/0.5% fish gelatin/0.1% Triton X-100). After blocking, the sections were treated overnight with primary antibody diluted in blocking buffer at 4°C. (Rabbit-anti-STIM1 1:50, Rabbit anti-Orai1 1:75, Rabbit-anti-CaMKIIδ2 1:50, Mouse-anti-smooth muscle myosin heavy chain, SM-MHC 1:50; and Mouse anti-Ki67 1:50). The sections were rinsed with washing buffer and then incubated with secondary antibody diluted in blocking buffer containing DAPI for 2 hours at room temperature. 488nm anti-rabbit secondary antibody (Molecular Probes) or 647nm anti-mouse secondary (Molecular Probes) diluted 1:200. Finally, the sections were mounted with anti-fade mounting media (Sigma). The sections were imaged using confocal microscopy at 63x. For Immunohistochemistry staining, frozen OCT sections were rinsed with 1x PBS 3 times and were fixed using either acetone at -20⁰C or 4% paraformaldehyde at room temperature for 10 minutes. Then sections were rinsed with 1 x PBS and endogenous peroxidase was quenched by incubating sections in 0.3% H 2 O 2 for 10 minutes followed by rinsing with 1x PBS. The sections were then incubated in blocking buffer (1x PBS/0.1% Tween-20/2% BSA, 5-10%serum) for 30-60 minutes, rinsed with 1x PBS, and incubated with primary antibody (diluted in 1x PBS/0.1%Tween-20/2%BSA) and incubated overnight at 4 o C. Primary antibodies dilutions were as follows: anti-Orai, 1:400; anti-STIM1, 1:2000 (Inset in Figure 6 , 1:1200); anti-SMα-actin, 1:800. Secondary antibodies were incubated with sections for 60 minutes at room temperature and sections were labeled by fresh ABC (Avidin/Biotinylated Enzyme Complex) for 30 minutes at room temperature. Substrate DAB (I drop DAB chromagen in 1mL DAB buffer) was added to sections for 2-5 minutes. Hematoxylin staining was performed for 45 seconds. Between every step, sections were rinsed with1x PBS. Paraffin sections were deparaffinized by Xylene for 10 minutes 2 times, rehydrated by ethanol (100%, 95%, 70%), rinsed with dH 2 O, and treated by Citra Plus 1X for 20-60 minutes. Then sections were rinsed by 1x PBS and incubated in blocking buffer (1x PBS/0.1% Tween-20/2% BSA, optional 1-2% serum) for 30 minutes. The remaining steps were similar to those used for OCT sections.
Protein Extraction and Western Blotting
The media (and neointima) of the carotid arteries were harvested by cutting open longitudinally and peeling off the adventitia. Tissues were used for protein extraction which was performed on ice. In brief, tissues were cut into small pieces and grinded with a homogenizer in the presence of cell lysis buffer : 10% Phosphatase Inhibitor, 10% Proteinase Inhibitor, and 1% PMSF in RIPA buffer (50mM Tris HCl, 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.2mM EDTA). After sonication and centrifugation of the cell lysate, proteins were quantified by BCA assay and then loaded in a 10-12% polyacrylamide gel at 10µg per lane. Diluted primary antibodies: Anti-Orai1 1:2000, Anti-STIM1 1:250 (BD biosciences), Anti-PCNA 1:100; Anti-GFP 1:1,000; Anti-CaMKIIδ2 1:1,000 and Anti-β-actin 1:40,000 were incubated overnight at 4⁰C, and diluted secondary antibodies (anti-rabbit 1:20,000 or anti-mouse 1:10,000) were incubated for 1 hour at room temperature. Membranes were developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Photos were taken by Fuji LAS4000 Imaging Station and band densities were quantified using the Image J software (NIH).
Real-time PCR
Experiments were conducted as described previously 1 . In brief, total RNA was extracted from cells using a Qiagen RNeasy Mini Kit following the manufacturer's protocol. cDNA was made from 0.5 μg of RNA reverse transcribed using oligo(dT) primers (Invitrogen, Carlsbad, CA, USA) and SuperScript III reverse transcriptase (Invitrogen). PCR reactions were completed using Illustra PuReTaq Ready-To-Go PCR beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The sense and antisense primers targeting rat STIM1, and Orai1 were described earlier 1 .
Real-time PCR analysis was performed using a Bio-Rad iCycler and iCycler iQ Optical System Software (Bio-Rad Laboratories). PCR reactions were performed using Bio-Rad iQ SYBR Green Supermix. The PCR protocol started with 5 min at 94°C, followed by 45 cycles of 30 s at 94°C, 30 s at 54.3°C, and 45 s at 72°C. Quantification was measured as sample fluorescence crossed a predetermined threshold value that was just above the background. Expressions of STIM1, or Orai1 were compared to those of the housekeeping gene rpL32 (Forward: 5'-GCCCAAGATCGTCAAAAAGA; Reverse:
5'-CGATGGCTTTTCGGTTCTTA) and were measured using comparative threshold cycle values as described previously 1 .
Ca
2+ measurements Ca 2+ measurements were performed as described previously 1, 4, 5 . Briefly, coverslips with attached cells were mounted in a Teflon chamber and incubated at 37°C for 45 min in culture media containing 4 μM Fura-2/acetoxymethyl ester (Molecular Probes, Eugene, OR, USA). Cells were then washed and bathed in HEPES-buffered saline solution (140 mM NaCl, 1.13 mM MgCl 2 , 4.7 mM KCl, 2 mM CaCl 2 , 10 mM D-glucose, and 10 mM HEPES, adjusted to pH 7.4 with NaOH) for at least 10 min before Ca 2+ measurements were made. For Ca 2+ measurements, fluorescence images of several cells were recorded and analyzed with a digital fluorescence imaging system (InCyt Im2; Intracellular Imaging Inc., Cincinnati, OH, USA). Fura-2 fluorescence at an emission wavelength of 510 nm was induced by exciting Fura-2 alternately at 340 and 380 nm. The 340/380 ratio images were obtained on a pixel-by-pixel basis. All experiments were conducted at room temperature.
Whole-cell patch-clamp electrophysiology
VSMCs were used for whole-cell patch-clamp recordings as described previously 1 and have a capacitance of 41.75 ± 11.71 pF. Patch pipettes of 2.5-to 4-MΩ were pulled from borosilicate glass capillaries (World Precision Instruments, Inc., Sarasota, FL, USA) with a P-97 flaming/brown micropipette puller (Sutter Instrument Company, Novato, CA, USA). Axopatch 200B and Digidata 1440A (Molecular Devices Corp., Sunnyvale, CA, USA) with pCLAMP 10 software were used for data acquisition and analysis. VSMCs were infected with shRNAencoding lentiviruses for 5 days before recordings. VSMCs were seeded on round coverslips 36 h before experiments. VSMCs were washed with bath solution containing 135 mM Namethanesulfonate, 10 mM CsCl, 1.2 mM MgSO 4 , 10 mM HEPES, 20 mM CaCl 2 , and 10 mM glucose (pH was adjusted to 7.4 with NaOH). Pipette solution contained 145 mM Csmethanesulfonate, 20 mM Cs-1,2-bis-(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 8 mM MgCl 2 , and 10 mM HEPES (pH adjusted to 7.2 with CsOH). Divalent-free (DVF) bath solution contained 155 mM Na-methanesulfonate, 10 mM N-hydroxyethylenediaminetriacetic acid, 1 mM EDTA, and 10 mM HEPES (pH 7.4, adjusted with HCl). Only cells with tight seals (>10 GΩ) were selected to break in. On obtaining a GΩ seal and break-in, recordings were made from cells with <10 MΩ series resistance. Cells were maintained at a 0 mV holding potential during experiments and subjected to voltage ramps from +100 to −150 mV lasting 250 ms every 2 s. "Reverse" ramps were designed to inhibit Na + channels, 10 μM verapamil was included in bath solution to inhibit L-type calcium channels, and 3 μM nimodipine was added to the bath solution to generally stabilize membrane patches and reach better seals.
NFAT-GFP translocation and NFAT luciferase activity assays
Due to the interference of shLuciferase lentivirus with the luciferase assay and that of GFP fluorescence encoded by the lentiviral particles with that of NFAT-GFP, we used siRNA electroporation instead of shRNA lentiviral infection of VSMC. Rat VSMCs were transfected by siRNA against STIM1, Orai1 or non-targeting control using electroporation (sequences provided above). After 3 days, these cells were transfected with pEGFP plasmid encoding nuclear factor for activated T cells (NFAT)-GFP fusion protein (addgene) or co-transfected with pIL-2-Luc (a generous gift from Dr. Fernando Macian) and Renilla-luciferase plasmid (minTK pRL). Twentyfour hours after transfection, cells were treated with 2µM Thapsigargin for 15 minutes. NFAT nuclear translocation was monitored by the GFP tag under the fluorescence microscope. NFAT activity was measured 24 hours after treatment with thapsigargin for 15 minutes in cell lysates by (firefly-)Luciferase assay using the Dual-Luciferase Reporter Assay Kit (Promega, Madison, WI), and normalized to Renilla-luciferase activity.
Statistical analysis
Data are expressed as means ± SE, and statistical analysis using One-way ANOVA was done with Origin software (OriginLab, Northampton, MA). *, ** and *** indicates p values < 0.05, 0.01 and 0.001 respectively. Differences were considered significant when P < 0.05. 
Legends to supplementary figures
